CoChat

Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time

Open access
Huot, Philippe, Johnston, Tom H., Lewis, Katie D., Koprich, James B., Reyes, M. Gabriela, Fox, Susan H., Piggott, Matthew J., Brotchie, Jonathan M. · 2011 · The Journal of Neuroscience
Cited by 81

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease, but long-term l-DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions of l-DOPA. MDMA is composed of two enantiomers with different pharmacological profiles; here, we describe a novel enantiospecific synthesis of the two enantiomers and expand on the previous characterization of their pharmacology.R-MDMA (rectus-MDMA) is relatively selective for 5-HT 2A receptors, whereas S-MDMA (sinister-MDMA) inhibits both serotonin (SERT) and dopamine transporters (DAT; SERT/DAT ratio of 10 to 1).R- or S-MDMA (1, 3, and 10 mg/kg, s.c.) was administered in combination with l-DOPA (15 mg/kg, s.c.) to six female common marmosets (Callithrix jacchus) rendered parkinsonian by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) administration. Motor disability, including parkinsonism and dyskinesia, and duration of antiparkinsonian benefit (ON-time) were evaluated. After the administration of R-MDMA (3 and 10 mg/kg), the severity of peak-dose dyskinesia was decreased (by 33 and 46%, respectively;p< 0.05); although total ON-time was unchanged (∼220 min), the duration of ON-time with disabling dyskinesia was decreased by 90 min when compared to l-DOPA alone (69% reduction;p< 0.05).S-MDMA (1 mg/kg) increased the total ON-time by 88 min compared to l-DOPA alone (34% increase;p< 0.05), though dyskinesia were exacerbated. These data suggest that racemic MDMA exerts simultaneous effects, reducing dyskinesia and extending ON-time, by 5-HT 2A antagonism and SERT-selective mixed monoamine uptake inhibition, which arise from its R and S enantiomers, respectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1171-11.2011

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 81

Metadata

Authors
Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., Piggott, M. J., & Brotchie, J. M.
Venue
The Journal of Neuroscience
Published
2011-05-11
Volume
31
Issue
19
Pages
7190-7198
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2152250507
Cited by
81
References
4
FWCI
3.84
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time. https://app.cochat.ai/papers/10.1523/jneurosci.1171-11.2011
The paper
Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., Piggott, M. J., & Brotchie, J. M. (2011). Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1171-11.2011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.